News Releases

Lykos Therapeutics Announces Changes to its Board of Directors

SAN JOSE, CA, Jan 14, 2025: Lykos Therapeutics (“Lykos”), a company dedicated to transforming mental health care, announced today changes to its board of directors. These transitions come as the company continues work towards resubmission of its new drug application and secures financing to support its strategy.

The changes include the following:

  • Independent Directors Jeff George, Scott Giacobello, and Jason Pyle, M.D., PhD., have stepped down from their respective board roles.
     
  • In addition, Kris Lotlikar, who previously served as a board member designated by The Multidisciplinary Association for Psychedelic Studies (MAPS), will leave his board role. MAPS, a Lykos shareholder, has designated two new directors to its existing board seats: Ron Beller and Joe Green. Dan Grossman, Ph.D., who previously filled one of these two seats, will remain on the board as an Independent Director.
     
  • Joseph McCowan, Psy.D., will also be joining the board, filling the seat occupied by Gisselle Acevedo, M.Ed., J.D., L.M.F.T., prior to her stepping down last month. Lastly, Independent Director Dawn McCollough and Preferred Director Suprotik Basu will remain in their respective roles.

“The outgoing members of the Lykos board, and in particular board chair Jeff George, provided strong governance, leadership and support for this company as it has navigated the challenge of bringing forward a pioneering treatment. The company is indebted to each of them for the expertise, sound judgement and tireless effort they provided,” said Lykos Interim CEO Mike Mullette. “In addition, I am pleased to welcome Lykos’ new members to the board, and I look forward to their collaboration as we move forward with the company’s important work.”

Through this transition, Lykos is working with several of its major shareholders, including Helena and MAPS, along with potential new investors, to secure an aligned go-forward financing strategy. The company will be providing further updates regarding its strategic path forward at the appropriate time. Lykos remains dedicated to its mission of bringing forward midomafetamine-assisted therapy for the more than 13 million Americans who suffer from PTSD.

Midomafetamine capsules have not been approved by any regulatory agency. The safety and efficacy of midomafetamine have not been established for the treatment of PTSD. Investigational midomafetamine is also being studied in other indications.